Zacks Company Profile for Invo BioScience Inc. (INVO : NSDQ) |
|
|
|
Company Description |
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.
Number of Employees: 12 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $1.56 |
Daily Weekly Monthly
 |
20 Day Moving Average: 32,348 shares |
Shares Outstanding: 12.09 (millions) |
Market Capitalization: $18.86 (millions) |
Beta: -0.40 |
52 Week High: $5.43 |
52 Week Low: $1.36 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-11.36% |
-2.88% |
12 Week |
-48.68% |
-44.32% |
Year To Date |
-53.15% |
-44.29% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Steven Shum - Chief Executive Officer
Andrea Goren - Chief Financial Officer
Matthew Szot - Director
Kevin Doody - Director
Trent Davis - Director
|
|
Peer Information
Invo BioScience Inc. (CORR.)
Invo BioScience Inc. (RSPI)
Invo BioScience Inc. (CGXP)
Invo BioScience Inc. (BGEN)
Invo BioScience Inc. (GTBP)
Invo BioScience Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 44984F302
SIC: 3841
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
|
|
Share - Related Items
Shares Outstanding: 12.09
Most Recent Split Date: 11.00 (0.63:1)
Beta: -0.40
Market Capitalization: $18.86 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.25 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-0.80 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/15/22 |
|
|
|
|